Biogen
NEWS
Genentech shared new data from its SUNFISH study evaluating the use of Evrysdi for SMA people ages 2 to 25 years diagnosed with Type 2 or Type 3 spinal muscular atrophy.
Biogen returned the rights to a dry age-related macular degeneration (dAMD) drug to Catalyst Biosciences. Biogen also ended the partnership regarding other dry AMD.
Biogen reported new data from a long-term extension phase of the Phase III clinical studies of Aduhelm (aducanumab) for Alzheimer’s disease.
Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).
In the latest results shared by the company, treatment with nusinersen for a median of 4.9 years helped participants maintain and make progressive gains in motor function.
Novartis released new data Monday from its Phase III SPR1NT trial that reinforces the benefits of Zolgensma.
After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
BioSpace compared the 43 healthcare and life science companies on Newsweek’s list of America’s Most Responsible Companies for 2022 with that of our own 2022 Best Places to Work.
JOBS
IN THE PRESS